Sichenzia Ross Friedman Ference LLP Advises Tonix Pharmaceuticals on $7.8 Million Public Offering
NEW YORK, July 16, 2014 (GLOBE NEWSWIRE) –New York based securities law firm, Sichenzia Ross Friedman Ference LLP, acted as counsel to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage pharmaceutical company focused on researching common disorders of the central nervous system, on a recently completed $7.8 million registered direct public offering pursuant to Tonix’s shelf registration statement. The offering consisted of 657,000 shares of common stock sold at $11.90 per share. Roth Capital Partners acted as the sole placement agent in this offering. The Sichenzia Ross Friedman Ference LLP team consisted of partners Marc J. Ross and James M. Turner and associate Sharon Carroll.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in $5.6 Million Underwritten Public Offering of Common Stock - June 11, 2019
- New Jersey Bureau of Securities Proposes New Rule to Create State-Level Fiduciary Duties For Broker-Dealers, Associated Persons, Investment Advisers and Investment Adviser Representatives - June 11, 2019
- Sichenzia Ross Ference LLP Represents Medicine Man Technologies, Inc. in Private Placement Offering of up to $14 Million - June 11, 2019